AIFMD2: The next (r)evolution?
Client memorandum | November 21, 2023
After several years of deliberation as to the revisions to the Alternative Investment Fund Managers Directive (“AIFMD”), an unofficial final text of the Amending Directive (“AIFMD2”) was published in November 2023 reflecting the compromise position agreed after the extensive trialogue discussions between the European Commission (“Commission”), European Council (“Council”), and European Parliament (“Parliament”).
Whereas AIFMD originally represented a dramatic shift in the regulation of private funds in Europe, AIFMD2 is considerably less revolutionary. The significance of an introduction of an AIF loan origination regime should not be understated, but that aside, the various targeted amendments made represent an evolution of the existing legislation rather than anything more fundamental, for which the industry should take considerable comfort, given some of the proposals that led us here today—see in particular our previous commentary on the letter from the European Securities and Markets Authority (“ESMA”) to the Commission outlining ESMA’s suggested improvements.
AIFMD2 is currently expected to enter into force early Q2 2024, meaning it will need to be transposed into national law by European Member States by early Q2 2026, subject to any specified grandfathering measures.
For those that have followed the trialogue in any detail, we have prepared a summary table comparing key provisions of the original Commission text with the revisions proposed by the Council and Parliament and the unofficial final text, included as an Annex to this note.
A high-level summary follows:
1. Loan Origination
As mentioned above, this is probably the most meaningful change, at least for those funds engaged in loan origination activity. Whilst Europe now has a significant market for loan originating funds, this industry was in its infancy when AIFMD entered into force 12 years ago, and this is the first attempt to regulate loan origination by AIFs at a European level. As would be expected—there are pros and cons in the draft.
The existence of the regime at all is to be welcomed, as is the explicit recognition that as part of its authorisation as AIFM, a manager will be permitted to carry out loan origination activity (not to be taken as a given, in light of the restrictive regulatory regime in certain European jurisdictions). It has also now been recognised that a loan origination fund can be open-ended (which the industry temporarily feared might not have been the case), subject to demonstrating satisfactory liquidity management arrangements.
Less welcome however will be hard leverage limits of no more than 300% (for closed-ended) and 175% (for open-ended) funds, though as with the first AIFMD, subscription facilities and other “borrowing arrangements which are fully covered by capital commitments” will be excluded from the calculation. There is an exemption for “shareholder loans,” representing a concession for the private equity industry, though the definition leaves room for argument about its scope and application.
Other restrictions under the regime include concentration limits restricting lending to a single financial undertaking or other fund to 20% of the capital of the originating fund, a prohibition on lending to related parties, a prohibition on funds pursing an originate-to-distribute strategy, and a 5% “skin in the game” risk retention requirement—which is itself interesting, since whilst this is consistent with the approach seen in other European legislation, it is the first time it has been applied to simple lending.
Crucially, there are grandfathering provisions that will allow existing funds formed before AIFMD2 comes into force (which, as mentioned above, is likely to be next year) to be managed without regard to the concentration limit, leverage limit or (for open-ended funds) liquidity management requirements for a further five years—though even during that grandfathering period, funds that raise new capital need not comply with these provisions, but may not increase the concentration or leverage any further than the level at which it stands when AIFMD2 comes into force. This restriction does not apply to existing funds that do not raise additional capital after AIFMD2 comes into force, which will simply be deemed to comply.
Notwithstanding the publication of the final text, there remain various known unknowns, and a number of interesting interpretational questions will doubtless arise over the next couple of years. For instance, “loan” is not defined in AIFMD2, and the definitions of “loan origination” and “loan originating AIFs” we do have are not entirely satisfactory. National implementation will also need to be monitored carefully. Though the stated intention of the AIFMD2 loan origination regime is to set down a common set of rules with a view to enabling loan originating AIFs to originate loans across the EU, the recitals provide that Member States should not be prevented from setting national product frameworks. In addition, the regime does not apply to non-EU managers of AIFs that originate loans in the EU, and so it is not inconceivable that the implementation of AIFMD2 in certain Member States could lead to a less favourable regulatory position for such managers.
2. Substance and Delegation
Existing substance requirements are expanded somewhat, with a requirement that the two senior managers required at present must be committed to the authorised manager on a full-time basis, either as employees or as members of the governing body. Funds being marketed to retail investors will also be “encouraged” to appoint at least one non-executive director to their governing body, but this is no longer a mandatory requirement (as was previously proposed).
There are also additional rules around delegation, with managers required to notify their competent authorities of any intention to delegate an expanded list of functions and to report on the operation of such delegation as part of their periodic reporting obligations. This includes quantitative data that has the potential to be sensitive, including (where the portfolio management function is delegated) the amount and percentage of a fund’s assets which are subject to delegation arrangements, as well as the number of full-time human resources employed to monitor delegation arrangements.
3. Liquidity Management
There are extensive revisions to the existing liquidity management requirements in AIFMD, with open-ended funds required to select at least two (or, for European money market funds, one) liquidity management tools (“LMTs”) from a specified list included in a new Annex V. The possibility and conditions for using such LMTs must be disclosed to prospective investors in accordance with Article 23 AIFMD, and the use of such LMTs must be notified to the relevant manager’s competent authority and, in certain cases, to investors.
Suspension and side-pocketing will be permitted in certain circumstances, with competent authorities able to require suspension in certain circumstances.
4. Depositary
The existing depositary regime has been slightly relaxed, with new provisions allowing the appointment of a depositary in a different European jurisdiction to that of the fund (though this new concession still falls short of a full cross-border depositary passport).
A depositary may be appointed in a different jurisdiction to that of the fund where there is a limited supply of depositaries in the relevant jurisdiction, which is to be determined by reference to the aggregate amount of assets held locally in custody.
This is subject to various conditions, including approval by the relevant competent authority, and the Commission will meanwhile be charged with considering introduction of a full cross-border depositary passport.
5. Third-Party AIFMs
There are additional rules for third-party “hosted” AIFMs requiring additional consideration of conflicts of interest and how they can be prevented (or, where this is not possible, identified, managed, monitored, and disclosed), with ESMA mandated to prepare a report for the Commission on the requirements applicable to third-party AIFMs and the need for any additional safeguards. Whilst these new conflict of interest rules, taken together with the additional transparency requirements around delegation, may be somewhat uncomfortable for the third-party AIFM industry, the rules are far less burdensome than they could have been.
6. Distribution and Marketing
There are some changes to the requirements for marketing of funds by non-European managers under national private placement regimes (“NPPR”), with the existing reference in Article 42 AIFMD to FATF non-cooperative countries and territories replaced by a reference to the EU AML blacklist maintained in accordance with the Fourth Anti-Money Laundering Directive, which has the potential to cause issues for Cayman funds in the future. In addition, the relevant third country jurisdiction would need to have signed an agreement with each Member State in which the fund is to be marketed which fully complies with the standards laid down in Article 26 of the OECD Model Tax Convention, and must not be on the EU list of non-cooperative tax jurisdictions.
Aside from conditions to marketing under NPPR, there is also reference in the delegation provisions to marketing carried out by distributors acting on their own behalf whilst marketing under MiFID II or the Insurance Distribution Directive not constituting a delegation by the relevant manager, though it is not entirely clear how this is intended to operate in practice, given the way in which “marketing” is defined in the first place (i.e., an offering or placement carried out at the initiative of the AIFM or on behalf of the AIFM). It is also unclear whether this implies that marketing conducted by persons who are not licensed under said directives (which would include certain investment consultants, as well as non-EU placement agents) represents a delegation of the marketing function.
7. Disclosure
The existing pre-investment and periodic disclosures required under Article 23 AIFMD are to be revised to include additional information about fees, charges, and expenses; LMTs for open-ended AIFs (referenced above); the use of parent, subsidiary, or SPV arrangements in connection with a fund’s investments; and a fund’s originated loan portfolios (where relevant).
8. Reporting
AIFMD2 leaves the door open for a potentially significant extension to Annex IV reporting requirements. Whereas, at present, an EU AIFM has to report on the “principal” markets and instruments in which it trades, and provide information on the main instruments in which it is trading and on the principal exposures and most important concentrations of each of the AIFs it manages, under AIFMD2, this will be extended to all markets, instruments, and exposures. As noted above, Annex IV reports will also be required to include additional information on delegation arrangements, as well as a list of all Member States in which the fund is marketed. The full impact of these changes will not be known until the Level 2 measures are produced.
With the possible exception of the loan origination regime, most of these amendments can really be regarded as fine tuning rather than anything more seismic, though as always what will be worth watching is the extent to which the industry adapts to accommodate the required changes, and the manner in which Member States implement where there is scope for discretion.
The Fried Frank London Regulatory Team has been closely following AIFMD2 since the review process first began. If you would like to discuss how AIFMD2 is likely impact you, please get in touch with Gregg Beechey, Zac Mellor-Clark, Nishkaam Paul, or your usual Fried Frank contact.
This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.